ORCID
- Hobart, Jeremy: 0000-0002-2114-7920
DOI
10.1016/j.msard.2022.103894
Publication Date
2022-07-01
Publication Title
Multiple Sclerosis and Related Disorders
Volume
63
ISSN
2211-0348
Embargo Period
2022-07-02
Organisational Unit
Peninsula Medical School
Recommended Citation
Dobson, R., Craner, M., Waddingham, E., Miller, A., Pindoria, J., Cavey, A., Blain, C., De, L., Evangelou, N., Ford, H., Gallagher, P., George, K., Geraldes, R., Harman, P., Hobart, J., King, T., Linighan, R., MacDougall, N., Marta, M., Mitchell, S., Nicholas, R., Rog, D., Scalfari, A., Scolding, N., Webb, S., White, S., Wilton, J., Young, C., & Matthews, P. (2022) 'Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)', Multiple Sclerosis and Related Disorders, 63. Available at: https://doi.org/10.1016/j.msard.2022.103894
